B+
Bull case
25%
Probability
Target price
$115.00
Analysis reference price unavailable
Analysis 2026-05-03 · RankAlpha Sentiment Codex
KYMR
Kymera TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The post-earnings bull read is that Q1 reinforced balance-sheet durability and platform breadth: cash, cash equivalents and investments were $1.55 billion at March 31, 2026 with runway into 2029, KT-579 entered Phase 1, and Gilead’s exercised KT-200 option adds a $45 million milestone [#8-K-2026-04-30]. Secondary coverage also framed the quarter as better than expected, with Zacks reporting EPS of -$0.71 versus a -$0.89 consensus and revenue above expectations.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +4.7.
What can break
KT-579 is only in Phase 1 healthy volunteers, so the program still faces classic early-stage safety, pharmacodynamic, and translation risk [#8-K-2026-04-30].
Momentum
77
Value
41
Sentiment
33
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $90.00 · Bull $115.00 · Bear $62.00Analysis 2026-05-03; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-03 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $136.77
Why
Momentum77 · Δ7d -11.4
Value41 · Δ7d -0.0
Sentiment33 · Δ7d +4.7
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +4.7.
Contradictions & invalidation
- • KT-579 is only in Phase 1 healthy volunteers, so the program still faces classic early-stage safety, pharmacodynamic, and translation risk [#8-K-2026-04-30].
- • KT-621 value still depends on successful Phase 2b execution in atopic dermatitis and asthma, with pivotal efficacy proof pushed into 2027 timelines [#8-K-2026-04-30].
- • The bear read is that the quarter did not materially de-risk the core valuation question, which still depends on later KT-621 and KT-579 clinical readouts rather than current-period P&L.
Catalyst clock
2026-05-31
May 2026 KT-621 medical-meeting presentations
Lead driver: Sentiment · See AI snapshot
Momentum
77
9% active weight
Current posture
7d trendSoftening
Δ7d
-11.4
Δ21d
-5.5
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
33
62% active weight
Current posture
7d trendImproving
Δ7d
+4.7
Δ21d
+9.8
Why this grade
Composite grade D. Momentum 77.4 / Value 41.2 / Sentiment 33.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-03. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$90.00
Analysis reference price unavailable
Analysis 2026-05-03 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$62.00
Analysis reference price unavailable
Analysis 2026-05-03 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$10.1B
Beta
2.22
Shares Out
83.15M
P/E (TTM) · Derived
-32.9
P/S (TTM)
132.11
P/FCF (TTM) · Derived
-48.05
Rev YoY
+466.4%
EPS YoY
-34.5%
Gross Margin
+92.2%
Op Margin
-329.8%
Net Debt
-$766.02M
Current Ratio
10.34
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data